|
1
|
Ozono S, Sakashita K, Yoshida N, Kakuda H, Watanabe K, Maeda M, Ishida Y, Manabe A, Taga T, Muramatsu H. A nationwide survey of late effects in survivors of juvenile myelomonocytic leukemia in Japan. Pediatr Blood Cancer 2023; 70:e30126. [PMID: 36495260 DOI: 10.1002/pbc.30126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Revised: 10/21/2022] [Accepted: 11/09/2022] [Indexed: 12/14/2022]
Abstract
We conducted a cross-sectional study using a questionnaire to explore the late effects in survivors of allogenic hematopoietic stem cell transplantation (HSCT) for juvenile myelomonocytic leukemia (JMML). The attending pediatric hematologists/oncologists completed the questionnaires. Of the 30 survivors, approximately 83% showed more than one late effect. The identified late effects included endocrine, dental, skin, ophthalmologic, musculoskeletal, pulmonary, neurocognitive, and cardiovascular dysfunction. The prevalence of short stature, pulmonary, cardiovascular, and nephrological complications was significantly elevated among survivors who were 12 years or more lapsed after HSCT. Therefore, a multidisciplinary follow-up system for survivors of JMML is crucial.
Collapse
Affiliation(s)
- Shuichi Ozono
- Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan
- Japan Children's Cancer Group (JCCG), Tokyo, Japan
| | - Kazuo Sakashita
- Japan Children's Cancer Group (JCCG), Tokyo, Japan
- Department of Hemato-Oncology, Nagano Prefectural Children's Hospital, Nagano, Japan
| | - Nao Yoshida
- Japan Children's Cancer Group (JCCG), Tokyo, Japan
- Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
| | - Harumi Kakuda
- Japan Children's Cancer Group (JCCG), Tokyo, Japan
- Department of Hemato-Oncology, Chiba Prefectural Children's Hospital, Chiba, Japan
| | - Kenichiro Watanabe
- Japan Children's Cancer Group (JCCG), Tokyo, Japan
- Department of Hemato-Oncology, Shizuoka Prefectural Children's Hospital, Shizuoka, Japan
| | - Miho Maeda
- Japan Children's Cancer Group (JCCG), Tokyo, Japan
- Department of Pediatrics, Nippon Medical School, Tokyo, Japan
| | - Yasushi Ishida
- Japan Children's Cancer Group (JCCG), Tokyo, Japan
- Department of Pediatrics, Ehime Prefectural Central Hospital, Ehime, Japan
| | - Atsushi Manabe
- Japan Children's Cancer Group (JCCG), Tokyo, Japan
- Department of Pediatrics, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan
| | - Takashi Taga
- Japan Children's Cancer Group (JCCG), Tokyo, Japan
- Department of Pediatrics, Shiga Medical College, School of Medicine, Shiga, Japan
| | - Hideki Muramatsu
- Japan Children's Cancer Group (JCCG), Tokyo, Japan
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
|
2
|
Shiba N, Taki T, Park MJ, Shimada A, Sotomatsu M, Adachi S, Tawa A, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Arakawa H, Hayashi Y. DNMT3A mutations are rare in childhood acute myeloid leukaemia, myelodysplastic syndromes and juvenile myelomonocytic leukaemia. Br J Haematol 2011; 156:413-4. [PMID: 21981547 DOI: 10.1111/j.1365-2141.2011.08879.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
MESH Headings
- Acute Disease
- Adolescent
- Age of Onset
- Bone Marrow Cells/metabolism
- Child
- Child, Preschool
- DNA (Cytosine-5-)-Methyltransferases/genetics
- DNA Methyltransferase 3A
- Exons/genetics
- Female
- Humans
- Infant
- Infant, Newborn
- Japan/epidemiology
- Leukemia, Myeloid/epidemiology
- Leukemia, Myeloid/genetics
- Leukemia, Myelomonocytic, Juvenile/epidemiology
- Leukemia, Myelomonocytic, Juvenile/genetics
- Male
- Myelodysplastic Syndromes/epidemiology
- Myelodysplastic Syndromes/genetics
- Neoplasms, Second Primary/epidemiology
- Neoplasms, Second Primary/genetics
- Nuclear Proteins/genetics
- Nucleophosmin
- RNA, Messenger/genetics
- RNA, Neoplasm/genetics
- fms-Like Tyrosine Kinase 3/genetics
Collapse
|
|
3
|
AlGhamdi KM, Al Suwaidan SN. Penile juvenile xanthogranuloma and neurofibromatosis type-1: risk association with juvenile myelomonocytic leukaemia? East Mediterr Health J 2010; 16:451-454. [PMID: 20795434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
MESH Headings
- Aftercare
- Biopsy
- Child, Preschool
- Humans
- Leukemia, Myelomonocytic, Juvenile/diagnosis
- Leukemia, Myelomonocytic, Juvenile/epidemiology
- Leukemia, Myelomonocytic, Juvenile/etiology
- Male
- Mass Screening
- Neurofibromatosis 1/complications
- Neurofibromatosis 1/diagnosis
- Neurofibromatosis 1/epidemiology
- Penile Diseases/complications
- Penile Diseases/diagnosis
- Penile Diseases/epidemiology
- Risk Factors
- Saudi Arabia/epidemiology
- Xanthogranuloma, Juvenile/complications
- Xanthogranuloma, Juvenile/diagnosis
- Xanthogranuloma, Juvenile/epidemiology
Collapse
Affiliation(s)
- K M AlGhamdi
- Department of Dermatology, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
| | | |
Collapse
|
|
4
|
Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res 2009; 33:355-62. [PMID: 18954903 PMCID: PMC2692866 DOI: 10.1016/j.leukres.2008.08.022] [Citation(s) in RCA: 108] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2008] [Revised: 08/15/2008] [Accepted: 08/19/2008] [Indexed: 02/02/2023]
Abstract
Juvenile myelomonocytic leukemia (JMML) is an aggressive childhood myeloproliferative disorder characterized by the overproduction of myelomonocytic cells. JMML incidence approaches 1.2/million persons in the United States (Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995). Although rare, JMML is innately informative as the molecular genetics of this disease implicates hyperactive Ras as an essential initiating event. Given that Ras is one of the most frequently mutated oncogenes in human cancer, findings from this disease are applicable to more genetically diverse and complex adult leukemias. The JMML Foundation (www.jmmlfoundation.org) was founded by parent advocates dedicated to finding a cure for this disease. They work to bring investigators together in a collaborative manner. This article summarizes key presentations from The Second International JMML Symposium, on 7-8 December 2007 in Atlanta, GA. A list of all participants is in Supplementary Table.
Collapse
Affiliation(s)
- Rebecca J. Chan
- Departments of Pediatrics, the Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Todd Cooper
- Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Christian P. Kratz
- Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany
| | - Brian Weiss
- Department of Pediatrics, Division of Pediatric Hematology/Oncology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Mignon L. Loh
- Department of Pediatrics, University of California, San Francisco, CA, USA
| |
Collapse
|